Analyse Century Therapeutics, Inc. (IPSC) — Kairos Score 58/100

À propos de Century Therapeutics, Inc.

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Informations clés

🕴️ Activité des initiés (90 jours)

7 transactions — 0 achats et 4 ventes déclarés par les dirigeants de Century Therapeutics, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur IPSC dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur IPSC.

• Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
• Century Therapeutics Appoints Joseph Truitt to Board of Directors

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.